Project Grant W81XWH2210994
Award Date 9/1/22
Completion Date 8/31/26
Dollars Obligated $1.9M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cypress, CA 90630, USA
Similar Awards
- Hbvtech received a $279,854 project grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will support Hbvtech's research from May 2021 through April 2023 to develop a novel hepatitis B virus drug aimed at effectively curing chronic hepatitis B. The Military Medical Research and Development program seeks to transform military and public health through innovative medical research solutions,...
- The Department of the Army Medical Command awarded a $5.5 million Project Grant to Carogen Corporation to support the Combination of HBV Immunotherapy with shRNA-Mediated PD-1/PDL Checkpoint Inhibition for Treatment of Chronic HBV from September 15, 2022 through September 14, 2025. This funding supports research under the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research and develop...
- This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $629,992.00 to Carogen Corp to test the safety and efficacy of CARG-201, an RNA replicon-based therapeutic vaccine for the treatment of chronic hepatitis B virus. The award period runs from September 1, 2024 to August 31, 2025. Carogen Corp, a minority-owned and small disadvantaged biopharmaceutical business, specializes in developing innovative...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $258,750 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to HBVTech, LLC, a small disadvantaged business located in Germantown, Maryland. The grant funding supports the development of HBVZ10, a new gene therapy candidate aimed at producing sustained high levels of anti-hepatitis B surface antigen antibodies to block hepatitis B virus (HBV) reinfection and potentially...
- This federal Project Grant award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a therapeutic nucleic acid vaccine for chronic hepatitis B virus (HBV) infections in HIV/HBV co-infected individuals. The awardee, Orlance, Inc., a woman-owned small business in Seattle, Washington, is leveraging its innovative MACH-1 gene gun technology to efficiently deliver DNA...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $320,863 to Jericho Sciences, LLC to support the translational development of a small molecule therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The project aims to validate the proposed drug target, the hepatitis B X regulatory protein (HBx), which plays a critical role in HBV covalently...
- The federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,480,488 to Brigham & Women's Hospital Inc. to research the combination of mRNA nanotherapy with standard antiangiogenic/immunotherapy for hepatocellular carcinoma (HCC). The research project runs from September 1, 2023 to August 31, 2026. As part of this effort, Massachusetts General Hospital will conduct preclinical studies to evaluate the...
- This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
- This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...